Certain Options of Achieve Life Sciences, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2021.
August 22, 2021
Share
Certain Options of Achieve Life Sciences, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2021. These Options will be under lockup for 90 days starting from 25-MAY-2021 to 23-AUG-2021.
Details:
The executive officers and directors have agreed to a 90-day “lock-up” with respect to shares of the common stock and other securities beneficially owned, including securities that are convertible into, or exchangeable or exercisable for, shares of the common stock. Subject to certain exceptions, during the applicable lock-up period following the date of this prospectus supplement, we and our executive officers and directors may not offer, sell, pledge or otherwise dispose of these securities without the prior written consent of Oppenheimer & Co. Inc.
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Companyâs product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.
ACHIEVE LIFE SCIENCES, INC. 
